Like so many of my late summer meals, this one revolves around fresh sweet corn. The window for it at the market is nowhere ...

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...